Multiple Myeloma
The past decade has witnessed dramatic progress in the treatment of multiple myeloma (MM), which has resulted in unprecedented improvements in survival outcomes.
Recent advancements in the treatment of multiple myeloma (MM) have led to
significant improvements in patient outcomes, including unprecedented survival
rates. Such progress has allowed a paradigm shift toward a chronic care
model, with attention increasingly focused on improving patients’ quality of life.
Oral oncolytics offer the ease of self-administration to patients. There is
no prodding for stubborn veins, and no need for a port. Therefore, oral therapies
empower patients, and often lead to improved quality of life.
